Literature DB >> 23887383

Residual antimicrobial effect of chlorhexidine digluconate and octenidine dihydrochloride on reconstructed human epidermis.

G Müller1, J Langer, J Siebert, A Kramer.   

Abstract

The objective of the present investigation was to examine the residual antimicrobial activity after a topical exposure of reconstructed human epidermis (RHE) to equimolar solutions of either chlorhexidine digluconate (CHG, 0.144% w/v) or octenidine dihydrochloride (OCT, 0.1% w/v) for 15 min. RHE-associated antiseptic agents were more effective on Staphylococcus aureus than on Pseudomonas aeruginosa. S. aureus was not detected after 24 h of contact, which demonstrated a microbicidal efficacy of greater than 5-log10 reduction. In contrast, P. aeruginosa was reduced by approximately 2 log10 at the same incubation time, which parallels the growth of the initial inoculum. This result could be interpreted either as a microbiostatic effect or as an adherence of P. aeruginosa to a low positively charged surface. Small amounts of CHG and OCT can penetrate the stratum corneum. Using these antiseptic agents, the viability of keratinocytes was reduced to 65-75% of that of the untreated RHE control following 24 h incubation in the presence of test microorganisms. With consideration of antimicrobial activity and cytotoxic effect, OCT corresponds better to a biocompatible antiseptic agent than CHG.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23887383     DOI: 10.1159/000350172

Source DB:  PubMed          Journal:  Skin Pharmacol Physiol        ISSN: 1660-5527            Impact factor:   3.479


  8 in total

1.  Eradication of MRSA skull base osteitis by combined treatment with antibiotics and sinonasal irrigation with sodium hypochlorite.

Authors:  I Küster; A Kramer; T Bremert; S Langner; W Hosemann; Achim G Beule
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-07-31       Impact factor: 2.503

Review 2.  Antiseptic use in the neonatal intensive care unit - a dilemma in clinical practice: An evidence based review.

Authors:  Sundar Sathiyamurthy; Jayanta Banerjee; Sunit V Godambe
Journal:  World J Clin Pediatr       Date:  2016-05-08

3.  In vitro study on the disinfectability of two split-septum needle-free connection devices using different disinfection procedures.

Authors:  Steffen Engelhart; Martin Exner; Arne Simon
Journal:  GMS Hyg Infect Control       Date:  2015-12-09

4.  Antimicrobial efficacy of the combination of chlorhexidine digluconate and dexpanthenol.

Authors:  Axel Kramer; Ojan Assadian; Torsten Koburger-Janssen
Journal:  GMS Hyg Infect Control       Date:  2016-12-14

5.  EFFECT of daily antiseptic body wash with octenidine on nosocomial primary bacteraemia and nosocomial multidrug-resistant organisms in intensive care units: design of a multicentre, cluster-randomised, double-blind, cross-over study.

Authors:  Anne Meißner; Dirk Hasenclever; Oana Brosteanu; Iris Freya Chaberny
Journal:  BMJ Open       Date:  2017-11-08       Impact factor: 2.692

6.  Comparison of the antimicrobial efficacy of povidone-iodine-alcohol versus chlorhexidine-alcohol for surgical skin preparation on the aerobic and anaerobic skin flora of the shoulder region.

Authors:  Dorothea Dörfel; Matthias Maiwald; Georg Daeschlein; Gerald Müller; Robert Hudek; Ojan Assadian; Günter Kampf; Thomas Kohlmann; Julian Camill Harnoss; Axel Kramer
Journal:  Antimicrob Resist Infect Control       Date:  2021-01-22       Impact factor: 4.887

7.  Efficacy of antifungal agents against fungal spores: An in vitro study using microplate laser nephelometry and an artificially infected 3D skin model.

Authors:  Sarah Fink; Anke Burmester; Uta-Christina Hipler; Claudia Neumeister; Marcus R Götz; Cornelia Wiegand
Journal:  Microbiologyopen       Date:  2022-02       Impact factor: 3.139

8.  Questions concerning "Chlorhexidine, octenidine, or povidone-iodine for catheter-related infections: A randomized controlled trial".

Authors:  Michael Braun; Jörg Siebert
Journal:  J Res Med Sci       Date:  2015-11       Impact factor: 1.852

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.